In the fight against COVID-19, PIMS Hydroxychloroquine (subsidiary of PureIMS) – together with (among others) the University of Groningen, UMCG and IMDS – is working feverishly on inhaled hydroxychloroquine. Following pulmonary administration, we expect a much greater effect of the drug with a lower chance of side effects, because it is administered directly to the site of infection with our easy-to-use, pre-loaded, disposable dry powder inhaler Cyclops™.
Full article (in Dutch) via this link: COVID-19: medicijn per inhaler mogelijk beter (Author: Frans van den Houdt; Chief editor ‘Pharmaceutisch weekblad’)